A Phase 4 interventional study of Ciprodiazole and Ciprofloxacin Tablets & Metronidazole tablets in Surgical Site Infections, sponsored by MinaPharm Pharmaceuticals. Status unknown at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-05-18.
Sponsored by MinaPharm Pharmaceuticals · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Surgical Wound Infection with a site in Egypt — 8 open to participants now, 10 under way, 1 of them phase 3. Surgical Wound Infection · Egypt.
Among the 27 studies in Surgical Wound Infection with a site in Egypt, this one is the 8th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2021, is one of 7 in phase 4, and was the 9th registered.
747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.
Browse Surgical Wound Infection studies →8 of the 27 studies in Surgical Wound Infection with a site in Egypt are open now. Recruiting first, the newest first:
Minia University · Sites in Egypt
Ages 18–75
Minia University · Sites in Egypt
Ages 18+
Beni-Suef University · Sites in Egypt
Ages 18–40 · Women only
ClinAmygate · Sites in Egypt
Ages 18–75
Mohamed Mousa Mohamed Mousa · Sites in Egypt
Women only · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2021.
This study's planned enrollment of 312 is above the median of 200 across 583 interventional studies indexed under Surgical Wound Infection.
Median enrollment 200 across the 23 interventional studies, 210 across the 4 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 27 have an industry lead sponsor. The 10 most frequent:
MinaPharm Pharmaceuticals is the lead sponsor of 7 studies on the registry; none are open to participants now.
MinaPharm Pharmaceuticals has 1 study filed under Surgical Wound Infection — fewer than ten, so there is no comparison to draw.
6 of the studies in Surgical Wound Infection with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07904143Alexandria UniversityPovidone-Iodine and Ozonated Distilled Water Irrigation in the Management of Maxillofacial Space Infections | 2027-01-30 |
| NCT07926100Alexandria UniversityRecognizing and Reporting Surgical Wound Complications After Discharge From Gastrointestinal Surgery in Egypt | 2027-02-24 |
| NCT07547826Assiut UniversityEfficacy and Cost-Effectiveness of Topical Vancomycin Powder in Preventing Pediatric Ventriculoperitoneal Shunt Infections Across Different Etiologies | 2027-05 |
| NCT07715409Mohamed Mousa Mohamed MousaEffect of Betadine Vaginal Cleansing Before Cesarean Section to Reduce Postoperative Infectious Morbidity | 2027-05-01 |
| NCT07720154Minia UniversityHernia Sac Flap Coverage of Mesh in Bony-Edged Ventral Hernia Repair | 2027-08-15 |
Add all 6 to your calendar (.ics) → With an account.
Among the 27 studies in Surgical Wound Infection with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to assess the safety \& efficacy of Oral Ciprodiazole® versus currently used Ciprofloxacin Tablets \& Metronidazole tablets in pelvi-abdominal infections and following IV antibiotics in post-operative period, for pelvi-abdominal surgeries or acute conditions
Primary Objective
Primary Safety:
To compare safety of oral Ciprodiazole ® tablets (Ciprofloxacin/Metronidazole) versus currently used Ciprofloxacin Tablets \& Metronidazole tablets for pelvi-abdominal infections, either non-operative or post-operative following IV antibiotics.
To compare efficacy of oral Ciprodiazole ® tablets (Ciprofolxacin/Metronidazole) versus currently used Ciprofloxacin Tablets \& Metronidazole tablets for pelvi-abdominal infections, either non-operative or post-operative following IV antibiotics.
Secondary Objective
Secondary Safety:
Secondary Efficacy:
STUDY DURATION:
STUDY POPULATION:
312 Egyptian Patients with pelvi-abdominal infection or started IV antibiotics in post-operative period, for pelvi - abdominal surgeries and/or acute conditions
ASSESSMENT SCHEDULE:
Subjects will be enrolled for 12 months including screening visit
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects with any medical condition requiring the usage of the following medications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ciprodiazole Tablets: (Ciprofloxacin 500 mg \& Metronidazole 500 mg), 1 tablet every 12 hours up to 15 days
Drug: Ciprodiazole
Ciprofloxacin 500 mg Tablets: 1 tablet every 12 hours up to 15 days Metronidazole 500 mg tablets: 1 tablet every 8 hours up to 10 days
Drug: Ciprofloxacin Tablets & Metronidazole tablets
Ciprofolxacin 500 mg / Metronidazole 500 mg
Drug pages: CiprofloxacinStudies of CiprofloxacinCiprofloxacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MetronidazoleStudies of MetronidazoleMetronidazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Ciprofolxacin 500 mg + Metronidazole 500 mg
Safety and Tolerability
Incidence of serious/ non-serious adverse events
Time frame: Up to 15 Days
Wounds healing
Complete healing of the of post-operative wounds
Time frame: Up to 15 Days
Resolution of pelvi-abdominal infection
Complete resolution for pelvi-abdominal infection, based on clinical response and/or pelvi-abdominal ultrasound and others
Time frame: Up to 15 Days
Signs of post-operative wound infection
Presence of any signs of post-operative wound infection such as redness, fever or wound discharge
Time frame: Up to 15 Days
Change in Safety Lab measures
Change in Total Leukocyte count and serum Liver enzymes (SGOT, SGPT) between baseline (visit 1) to End of study visit (Follow up 2 V)
Time frame: Up to 15 Days
Infection outcome
Complete resolution, improvement, failure or relapse of pelvi-abdominal infection, based on pelvi-abdominal ultrasound and/or clinical response
Time frame: Up to 15 Days
Healing Days
Days for complete healing of post-operative wounds between the 2 groups
Time frame: Up to 15 Days
PDFs hosted by the registry, ClinicalTrials.gov.
Started Aug 2021 (actual). Primary completion is estimated for Dec 2023, 28 months after the start.
Of 47 phase 4 interventional studies under Surgical Wound Infection, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's planned 28 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MinaPharm Pharmaceuticals